Clinical Trial Update: Study of Lademirsen (SAR339375) in Patients With Alport Syndrome [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for Lademirsen (SAR339375) in Alport syndrome. The study has been terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alport Syndrome

Drugs mentioned

• Lademirsen (SAR339375)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Alport Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2023-10-23